2018年11月
Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia.
Annals of clinical and translational neurology
- 巻
- 5
- 号
- 11
- 開始ページ
- 1421
- 終了ページ
- 1427
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1002/acn3.654
- 出版者・発行元
- Annals of Clinical and Translational Neurology
Immune checkpoint inhibitors sometimes cause neuromuscular adverse events. Although a few cases of myasthenia gravis with hyperCKemia triggered by immune checkpoint inhibitors have been described, conclusive evidence remains limited. We conducted a systematic review of published cases of myasthenia gravis with hyperCKemia related to immune checkpoint inhibitors. Moreover, we tested anti-striational antibodies in the case of myasthenia gravis with myositis after nivolumab administration. We located 17 published case reports. Anti-striational antibodies were tested in six cases and five cases were positive. Our systematic analyses revealed poor prognosis in myasthenia gravis combined hyperCKemia with immune checkpoint inhibitors.
- リンク情報
- ID情報
-
- DOI : 10.1002/acn3.654
- PubMed ID : 30480036
- PubMed Central 記事ID : PMC6243386